3rd International Conference on Stem Cells, Regenerative Medicine & Tissue Engineering

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Stem cell

An unspecialised cell that can divide repeatedly and, under the right conditions, mature into one or more specialised cell types. Conference sessions usually separate pluripotent, multipotent (adult) and tissue-resident stem cell populations because their regulation, sourcing and clinical use differ sharply.

2

Pluripotent stem cell (PSC)

A cell able to form derivatives of all three germ layers (ectoderm, mesoderm, endoderm) but not a whole organism. Human embryonic stem cells and induced pluripotent stem cells are the two families most often discussed in regenerative medicine programmes.

3

iPSC (induced pluripotent stem cell)

An adult cell reprogrammed back to a pluripotent state with defined transcription factors or chemical cocktails. iPSCs allow patient-specific disease modelling and cell sourcing without embryos, but reprogramming efficiency, genomic stability and remaining epigenetic memory are recurring discussion points.

4

Mesenchymal stromal cell (MSC)

A fibroblast-like adherent cell population, commonly isolated from bone marrow, adipose tissue, umbilical cord or dental pulp, studied mainly for immunomodulation and tissue repair. MSC identity and potency assays remain a standardisation topic because surface marker panels alone do not predict function.

5

Hematopoietic stem cell transplantation (HSCT)

Infusion of hematopoietic stem cells, usually from bone marrow, peripheral blood or cord blood, to rebuild the blood and immune system after high-dose therapy. It is the most established stem cell therapy in routine clinical practice and a benchmark for newer cell products.

6

Directed differentiation

Stepwise exposure of stem cells to defined growth factors and small molecules to steer them toward a target cell type such as cardiomyocytes, dopaminergic neurons, hepatocytes or pancreatic beta cells. Protocol reproducibility and maturation state are frequent programme themes.

7

Organoid

A three-dimensional, self-organising tissue model grown from stem cells or progenitor cells that reproduces some architecture and function of an organ. Organoids are used for disease modelling, drug screening and, increasingly, as starting material for cell therapy research.

8

Advanced therapy medicinal product (ATMP)

The EU regulatory category covering gene therapy medicines, somatic cell therapy medicines, tissue-engineered products and combined ATMPs. ATMP classification determines the manufacturing, quality and clinical evidence package a developer must supply to EMA.

9

GMP-grade manufacturing

Production of cells or tissues under Good Manufacturing Practice, with documented cleanroom controls, validated processes, release testing and chain of identity. Translating an academic protocol into GMP-grade production is one of the costliest steps in cell therapy development.

10

CAR-T cell therapy

T cells engineered to express a chimeric antigen receptor that redirects them against a chosen surface antigen, widely used in selected haematological cancers. Solid tumour application, persistence and toxicity management are active research areas.

11

Extracellular vesicles / exosomes

Membrane-bound particles released by cells that carry proteins, lipids and RNA and can act as signalling intermediaries. They are studied both as biomarkers and as candidate cell-free therapeutics, with isolation and potency standardisation still debated.

12

CRISPR genome editing

A programmable nuclease system that creates targeted DNA breaks or base changes guided by an RNA sequence. In regenerative medicine it is used to correct disease mutations in patient cells, enhance graft survival and engineer allogeneic cell banks.

13

Scaffold and biomaterial

A natural or synthetic matrix that supports cell attachment, proliferation and three-dimensional tissue formation, sometimes loaded with growth factors. Material choice drives mechanical match, degradation rate and immune response in tissue engineering.

14

Immunogenicity and graft rejection

The recipient immune response against transplanted or infused cells, ranging from alloreactive T cell rejection to innate responses against xeno-free versus xeno-containing culture reagents. Allogeneic off-the-shelf products need immune evasion or immunosuppression strategies.

15

Translational research and first-in-human trial

The pathway from bench protocol to regulated clinical study, including pharmacology, dose selection, safety endpoints and manufacturing readiness. Conference tracks on translation typically cover IND or clinical trial application packages and potency assay qualification.

16

Bioreactor scale-up

Moving cell production from flasks to controlled stirred-tank, hollow-fibre or fixed-bed systems that deliver reproducible oxygen, nutrient and shear conditions. Scale-up decisions shape cost of goods and batch sizes for later-phase clinical supply.

17

Cryopreservation

Storing cells at ultra-low temperature, typically in dimethyl sulfoxide-containing media in liquid nitrogen vapour, while preserving viability after thaw. Freeze-thaw recovery and cold-chain logistics are practical constraints for any distributed cell therapy.